<DOC>
	<DOCNO>NCT01454076</DOCNO>
	<brief_summary>This open-label , multicenter , sequential , 5-arm , phase 1 study oral IXAZOMIB design assess drug-drug interaction ketoconazole ( Arm 1 ) , relative bioavailability 2 capsule formulation IXAZOMIB ( Arm 2 ) , food effect ( Arm 3 ) , drug-drug interaction rifampin ( Arm 4 ) , drug-drug interaction clarithromycin ( Arm 5 ) patient advance nonhematologic malignancy lymphoma .</brief_summary>
	<brief_title>Phase 1 Pharmacokinetics Study Oral IXAZOMIB Patients With Advanced Nonhematologic Malignancies Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Clarithromycin</mesh_term>
	<mesh_term>Ketoconazole</mesh_term>
	<mesh_term>Ixazomib</mesh_term>
	<mesh_term>Glycine</mesh_term>
	<criteria>Male female patient 18 year old Patients must diagnosis histologically cytologically confirm metastatic and/or advance solid tumor malignancy lymphoma effective standard treatment available Female patient postmenopausal least 1 year , OR surgically sterile , OR childbearing potential , agree practice 2 effective method contraception , time time sign consent form 90 day last dose study drug , agree practice true abstinence Male patient , even surgically sterilize , agree practice effective barrier contraception entire study treatment period 90 day last dose study drug OR agree practice true abstinence Voluntary write informed consent Clinical laboratory value specify protocol Suitable venous access Recovered ( ie , &lt; Grade 1 toxicity patient 's baseline status ) reversible effect prior anticancer therapy Peripheral neuropathy &gt; Grade 2 clinical examination Systemic treatment strong inhibitor CYP1A2 , strong inhibitor CYP3A , strong CYP3A inducer use ginkgo biloba St. John 's wort within 14 day first dose IXAZOMIB Patient symptomatic brain metastasis . Patients brain metastasis must : stable neurologic status follow surgery radiation least 2 week completion definitive therapy ; AND without neurologic dysfunction would confound evaluation neurologic adverse event Female patient pregnant lactate Serious illness could interfere protocol completion Autologous stem cell transplant within 6 month Day 1 Cycle 1 , prior allogeneic stem cell transplant time Prior treatment rituximab unconjugated antibody treatment within 42 day ( 21 day clear evidence progressive disease immediate treatment mandate ) Ongoing treatment corticosteroid Radiotherapy within 21 day first dose study drug Major surgery within 14 day first dose study drug Infection require systemic antibiotic therapy serious infection within 14 day prior first dose study drug Lifethreatening illness unrelated cancer Known human immunodeficiency virus ( HIV ) positive , hepatitis B surface antigenpositive , suspect hepatitis C infection Diagnosis treatment another malignancy within 2 year precede first dose , OR previously diagnose another malignancy evidence residual disease . Patients nonmelanoma skin cancer carcinoma situ type exclude undergone complete resection Evidence uncontrolled cardiovascular condition QTc &gt; 500 millisecond 12lead electrocardiogram ( ECG ) Known gastrointestinal disease procedure could interfere oral absorption tolerance IXAZOMIB include difficulty swallow capsule ; diarrhea &gt; Grade 1 despite supportive therapy Patients gastric achlorhydria Patients use nicotine containing product within 14 day first dose study drug ( Arm 1 , Arm 4 , Arm 5 ) Treatment investigational product systemic antineoplastic therapy within 21 day first dose IXAZOMIB</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Cmax : maximum plasma concentration</keyword>
	<keyword>AUC0-tlast : time zero time last quantifiable concentration</keyword>
</DOC>